InVitria

Heading to ASGCT 2026? Stop by Booth #909 to meet the InVitria team and learn how recombinant, animal-origin-free proteins are supporting gene and cell therapy workflows.

We’ll also be presenting about how to enhancing infectious lentiviral vector yields.
Title: Recombinant Animal-Free Albumin Enhances Infectious Lentiviral Vector Yields By Stabilizing Viral Particles During Downstream Processing and Final Formulation.
Presented by Mark Stathos, PhD
📍May 12 at 4:45 PM | Room 162AB

And presenting a poster:
📍 #2182
Title: Enhanced Cryopreservation of Therapeutically Relevant Cells: Superior Performance of Recombinant Albumin and Its Role in Reducing DMSO Dependency

See how recombinant albumin can support:
• Reduced-DMSO cryopreservation
• Post-thaw recovery
• Cell viability and expansion
• More defined manufacturing workflows

Day 2 in Nashville and the booth has been the best seat in the house. 👋

After Scott's talk yesterday on the recombinant albumin journey, the questions kept coming — about Exbumin® for lyophilized formulations, Optibumin® 25 for closed-system GMP workflows, and what it really takes to move away from plasma-derived HSA.

These are our favorite kinds of conversations: real problems, real formulations, real timelines.

If you're at IPEC Excipient World, come find Scott, Elliott and Jake at Booth #328 — we're here through tomorrow. ☕️

What does it take for a novel excipient to become a standard?

At the Biologics Summit, Scott Deeter broke down the recombinant albumin journey, including:
• Stability and performance considerations
• Regulatory path and adoption barriers
• Real-world use in approved biologics

Relevant for teams working on formulation, process consistency, or risk reduction.
The talk will be posted soon. Visit https://hubs.ly/Q04fjN6H0 to receive it directly